A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells
AUTOR(ES)
Garabedian, Emily M.
FONTE
The National Academy of Sciences
RESUMO
A transgenic mouse model of metastatic prostate cancer has been developed that is 100% penetrant in multiple pedigrees. Nucleotides −6500 to +34 of the mouse cryptdin-2 gene were used to direct expression of simian virus 40 T antigen to a subset of neuroendocrine cells in all lobes of the FVB/N mouse prostate. Transgene expression is initiated between 7 and 8 weeks of age and leads to development of prostatic intraepithelial neoplasia within a week. Prostatic intraepithelial neoplasia progresses rapidly to local invasion. Metastases to lymph nodes, liver, lung, and bone are common by 6 months. Tumorigenesis is not dependent on androgens. This model indicates that the neuroendocrine cell lineage of the prostate is exquisitely sensitive to transformation and provides insights about the significance of neuroendocrine differentiation in human prostate cancer.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=28051Documentos Relacionados
- A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype
- Prostate cancer in a transgenic mouse.
- Histopathological characteristics of a novel knock-in mouse prostate cancer model
- Hormonal therapy for metastatic prostate cancer.
- Inducible shRNA expression for application in a prostate cancer mouse model